Proteolysis targeting chimeras (PROTACs) represents a new paradigm in therapeutics, capable of targeting any binding site and driven by ternary complex formation. In cellular, the PROTAC undergo binary engagement with either the E3 ligase or the target protein, which primes ternary complex formation. Profacgen offers a wide range of methods, such as SPR, BLI, Co-IP and NMR, to evaluate the target-PROTAC-E3 ligase ternary formation for a designed PROTAC.

https://www.profacgen.com/ternary-complex-formation.htm

Profacgen offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy, world-class process development, cGMP manufacturing, and analytical development.